The US Patent and Trademark Office has issued Patent number 8,324,266, titled “Compositions, Methods & Systems for Respiratory Delivery of Two or More Active Agents,” to Pearl Therapeutics. The patent covers formulation methods using the company’s co-suspension technology in metered-dose inhalers (MDIs). Pearl says that “the technology effectively prevents the sedimentation of drug crystals inside MDI canisters, minimizes interaction of active agents either with canister components or with each other, and keeps active agents stable over long periods of time.”
The technology covered by the patent is used in Pearl’s PT003 fixed dose combination of glycopyrrolate (GP) and formoterol fumarate (FF) and PT010, an MDI that combines GP, FF and a corticosteroid. According to CEO Chuck Bramlage, the company plans to advance PT003 into Phase 3 trials in 2013.
Pearl cofounder and Executive VP, research and development Sarvajna Dwivedi commented, “We believe our co-suspension formulation technology, as described in this patent, is a key differentiator of Pearl’s combination product pipeline. . . . The issuance of this patent is a testament to the scientific innovation and engineering excellence of the Pearl team.”
View the patent.
Read the Pearl Therapeutics press release.
